Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
M. Saleh, M. Barve, V. Subbiah, K. P. Papadopoulos, D. Morgensztern, N. B. Mettu, S. Roychowdhury, I. Spanggaard, M. L. Veronese, C. Tian, I. M. Silverman, M. Gutierrez
Research output: Contribution to journal › Article › peer-review
1Citation
(Scopus)
Fingerprint
Dive into the research topics of 'Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies'. Together they form a unique fingerprint.